Understand the source comparison
Do Peptides Help with Mold Illness: Evidence vs Mechanism
Thymalin (thymic peptide) Stimulates thymulin production, upregulates CD4+CD25+FoxP3+ Treg cells, reduces pro-inflammatory cytokines Studied in immune reconstitution after chemotherapy, post-viral syndromes, autoimmune conditions Directly addresses Treg suppre
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin (thymic peptide)
- Stimulates thymulin production, upregulates CD4+CD25+FoxP3+ Treg cells, reduces pro-inflammatory cytokines
- Studied in immune reconstitution after chemotherapy, post-viral syndromes, autoimmune conditions
- Directly addresses Treg suppression and cytokine dysregulation seen in CIRS. TGF-β1 and IL-6 elevation
- Preclinical + Phase II trials in immune dysfunction; no CIRS-specific RCTs
- MK-677 (growth hormone secretagogue)
- Stimulates pulsatile GH/IGF-1 release, enhances mitochondrial biogenesis, promotes tissue repair
- Studied in sarcopenia, chronic fatigue syndrome, metabolic dysfunction
- Addresses mitochondrial impairment and tissue repair deficits common in post-mold states
- Phase III data in metabolic conditions; observational use in CFS
- KPV (melanocortin tripeptide)
- Inhibits NF-κB nuclear translocation, reduces TNF-α and IL-6 transcription
- Studied in IBD, rheumatoid arthritis, systemic inflammation models
- Directly targets constitutive NF-κB activation driving CIRS cytokine cascade
- Phase II trials in IBD; mechanistic overlap strong but no CIRS trials
- Cerebrolysin (neurotrophic peptide mix)
- Contains BDNF and NGF, promotes synaptic plasticity, reduces neuronal apoptosis
- Studied in stroke recovery, vascular dementia, traumatic brain injury
- Addresses neurocognitive dysfunction (brain fog, memory impairment) common in CIRS
- Meta-analyses show 18–24% cognitive improvement in vascular impairment
- Here's the honest answer: no peptide has been tested in a randomised controlled trial specifically for mold illness. What we have is mechanistic overlap. Peptides proven to modulate immune function, reduce specific inflammatory markers, or promote tissue repair in conditions with similar pathophysiology. Thymalin's ability to restore Treg populations matters because Treg suppression is a documented feature of CIRS. MK-677's GH/IGF-1 stimulation matters because mitochondrial dysfunction is measurable in mold-exposed patients. The leap from 'this mechanism is impaired in CIRS' to 'this peptide corrects it' is a reasonable hypothesis, not yet a clinical fact.